Centessa Pharmaceuticals (LTS:0ACX) Current Accrued Expense : $14.18 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Centessa Pharmaceuticals Current Accrued Expense?

Centessa Pharmaceuticals's Current Accrued Expense for the quarter that ended in Mar. 2025 was $14.18 Mil.

Centessa Pharmaceuticals's quarterly Current Accrued Expense increased from Sep. 2024 ($11.82 Mil) to Dec. 2024 ($39.85 Mil) but then declined from Dec. 2024 ($39.85 Mil) to Mar. 2025 ($14.18 Mil).

Centessa Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2022 ($14.97 Mil) to Dec. 2023 ($19.89 Mil) and increased from Dec. 2023 ($19.89 Mil) to Dec. 2024 ($39.85 Mil).

Centessa Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for Centessa Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals Current Accrued Expense Chart

Centessa Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

1.04

10.84

14.97

19.89

39.85

Centessa Pharmaceuticals Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial													16.02	16.16	11.82	39.85	14.18

Centessa Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Centessa Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Centessa Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (LTS:0ACX) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

CNTA:USA

Address

1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT

Website

https://www.centessa.com

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.

Centessa Pharmaceuticals Headlines

No Headlines